The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Patients with high-risk renal cell carcinoma (RCC) experience high rates of recurrence despite definitive surgical resection. Recent trials of adjuvant tyrosine kinase inhibitor therapy have provided conflicting efficacy results at the cost of significant adverse events. PD-1 blockade via monoclonal antibodies has emerged as an effective disease-modifying treatment for metastatic RCC. There is emerging data across other solid tumors of the potential efficacy of neoadjuvant PD-1 blockade, and preclinical evidence supporting a neoadjuvant over adjuvant approach. PROSPER RCC is a Phase III, randomized trial evaluating whether perioperative nivolumab increases recurrence-free survival in patients with high-risk RCC undergoing nephrectomy. The neoadjuvant component, intended to prime the immune system for enhanced efficacy, distinguishes PROSPER from other purely adjuvant studies and permits highly clinically relevant translational studies.

authors

  • Patel, Hiten D
  • Puligandla, Maneka
  • Shuch, Brian M
  • Leibovich, Bradley C
  • Kapoor, Anil
  • Master, Viraj A
  • Drake, Charles G
  • Heng, Daniel YC
  • Lara, Primo N
  • Choueiri, Toni K
  • Maskens, Deborah
  • Singer, Eric A
  • Eggener, Scott E
  • Svatek, Robert S
  • Stadler, Walter M
  • Cole, Suzanne
  • Signoretti, Sabina
  • Gupta, Rajan T
  • Michaelson, Marc Dror
  • McDermott, David F
  • Cella, David
  • Wagner, Lynne I
  • Haas, Naomi B
  • Carducci, Michael A
  • Harshman, Lauren C
  • Allaf, Mohamad E

publication date

  • May 2019